Germline mutations in genes encoding several components of the retinoblastoma pathway have been linked with inherited predisposition to melanoma. Most commonly, such mutations involve CDKN2A, a cyclindependant kinase inhibitor of two kinases, CDK4 and CDK6, which phosphorylate the retinoblastoma protein (pRB) and thereby promote passage through the G 1 /S cell-cycle restriction point. Less frequently, germline mutations in the CDK4 gene have also been linked with an increased risk of melanoma. Despite the sequence and functional homology between CDK4 and CDK6, the role of germline mutations in CDK6 in melanoma predisposition is unknown. We detected no CDK6 mutations within the p16 (CDKN2A) binding domain in index cases from 60 melanoma-prone kindreds that lacked germline mutations in the coding regions of either CDKN2A or within the entire CDK4 coding region. We conclude that germline mutations in CDK6 do not make a signi®cant contribution to melanoma predisposition.
Germline mutations in genes encoding several components of the retinoblastoma pathway have been linked with inherited predisposition to melanoma. Most commonly, such mutations involve CDKN2A, a cyclindependant kinase inhibitor of two kinases, CDK4 and CDK6, which phosphorylate the retinoblastoma protein (pRB) and thereby promote passage through the G 1 /S cell-cycle restriction point. Less frequently, germline mutations in the CDK4 gene have also been linked with an increased risk of melanoma. Despite the sequence and functional homology between CDK4 and CDK6, the role of germline mutations in CDK6 in melanoma predisposition is unknown. We detected no CDK6 mutations within the p16 (CDKN2A) binding domain in index cases from 60 melanoma-prone kindreds that lacked germline mutations in the coding regions of either CDKN2A or within the entire CDK4 coding region. We conclude that germline mutations in CDK6 do not make a signi®cant contribution to melanoma predisposition. Oncogene (2000) 19, 1849 ± 1852.
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Between 8 and 12% of melanoma cases arise in families with a genetic predisposition to the disease (Tucker and Goldstein, 1995) . In a subset of these kindreds, germline coding mutations of the CDKN2A gene (on human chromosome 9p21) co-segregate with cases of melanoma (Hussussian et al., 1994; Walker et al., 1995; Dracopoli and Fountain, 1996; FitzGerald et al., 1996; NL and DH, unpublished) . The CDKN2A gene product ± designated p16 ± is a cyclin-dependent kinase (CDK) inhibitor (CDKI). p16 plays a key regulatory role in the retinoblastoma (Rb) pathway at the G 1 /S cell-cycle restriction point by inhibiting the phosphorylation of Rb via CDK4/6 (Kato et al., 1993; Weinberg, 1995; Ruas and Peters, 1998) . The genetic basis for melanoma in families and individuals that lack coding mutations of CDKN2A is not well understood at this time. Possible explanations include non-coding mutations of CDKN2A; alterations in other genes located at 9p21; and mutations of other major or minor melanoma predisposition genes located elsewhere in the human genome.
Genetic alterations of two other members of the Rb pathway in addition to CDKN2A have been linked with an increased risk of melanoma. Individuals harbouring germline mutations in the Rb gene and who have retinoblastoma as children show an increased risk of melanoma as adults (Draper et al., 1986; Traboulsi et al., 1988; Eng et al., 1993; Bataille et al., 1995) . In addition, three melanoma prone families have been reported to possess germline mutations in the CDK4 gene that cosegregate with the disease. Two of these families possess a cysteine rather than the wild-type arginine at amino acid 24 (R24C; Zuo et al., 1996) . More recently, an additional mutation at position 24 (R24H) was identi®ed in a single French kindred (Sou®r et al., 1998) . Moreover, the R24C (and presumably the R24H) mutant protein has a reduced anity for p16, resulting in relaxation of control at the G1/S restriction point. CDK6 shows considerable amino acid homology with CDK4 ( Figure 1 ) and both proteins possess very similar 3D structure (Brotherton et al., 1998; Russo et al., 1998) . Functionally, both proteins bind cyclin D1 and are speci®cally inhibited by CDKN2A (Serrano et al., 1993) . We therefore hypothesized that germline mutations in CDK6 might predispose to melanoma.
We used direct sequencing and SSCP analysis to screen a single aected member from 60 melanomaprone families in which a minimum of two individuals had been diagnosed with either melanoma or pancreatic carcinoma (Table 1 ). Prior to the sequence analysis of CDK6, we screened each of the 60 DNA samples for CDKN2A and CDK4 germline mutations. The CDKN2A gene was analysed as outlined previously (Liu et al., 1995 (Liu et al., , 1999 . All of the patients analysed in this study lacked any functional mutations within 1 kilobase (kb) of the promoter and 5'UTR sequences directly upsteam of the ATG initiation codon and in exons 1 and 2 of the CDKN2A gene (data not shown). To determine whether any of these families harboured germline CDK4 mutations, we ®rst used PCR to generate a DNA fragment of approximately 1.4 KB, which encompassed exons 2 ± 5 of CDK4, and then analysed this fragment by direct cycle sequencing. We found no evidence of germline mutations within the sequenced product (corresponding to amino acids 1 ± 72 in the translated protein); speci®cally, we did not observe the R24C and R24H alterations described previously (Zuo et al., 1996; Sou®r et al., 1998) .
Mutations at various sites within the CDK4 coding sequence have been found to decrease the anity to CDK4 for p16 in in vitro binding assays. Among these are variations at amino acids 22, 25, 34 ± 35, 56, 95 ± 101, 181/184 and 281 ± 283 (Coleman et al., 1997; Luh et al., 1997; Byeon et al., 1998; Ceha et al., 1998) . These data suggest that at least some p16 binding sites reside outside of the established p16-binding pocket (amino acids 22 ± 25) or that mutations in these other regions result in conformation changes in CDK4, thereby prohibiting CDKN2A from accessing the binding pocket. In order to include these regions in our CDK4 screening, we looked for sequence variations in the six remaining translated exons (3 ± 8) of CDK4 using PCR-SSCP (Zuo et al., 1996) . We observed no variation in the banding pattern relative to wild-type (unaected) control DNA samples for any of the 60 patients across the six exons screened in this manner, including the putative p16-interactive motifs found in exon 3 (amino acids 95 ± 97; Luh et al., 1997; Ceha et al., 1998) , exon 5 (amino acids 181 and 184; Coleman et al., 1997) and exon 8 (amino acids 281 ± 283; Coleman et al., 1997; Ceha et al., 1998) .
The fact that both CDK4 and CDK6 bind cyclin D and p16 implies that these two CDKs share structural homology. Although the translated proteins are of slightly dierent lengths (CDK4 is 303 amino acids in length, whereas CDK6 is 326 amino acids), the two kinases exhibit 64.4% homology across the entire length of their peptide sequences. Notably, within the R31 region of CDK6 (R24 of CDK4) these two proteins show somewhat higher homology (67.6%; Figure 1 ). Since this region also corresponds to the CDKN2A-binding site in CDK4, we decided to examine the R31 region of CDK6.
As the genomic DNA sequence of CDK6 was unknown at the time we began this study, it was ®rst necessary to identify the putative intron/exon boundaries within the gene region, using the amino acid and cDNA nucleotide homology between CDK4 and CDK6 as a reference. Human genomic sequences corresponding to CDK6 were identi®ed from a BLAST search of GenBank (NCBI, NIH) using the published CDK6 cDNA sequence (also known as PLSTIRE; GenBank Accession Number X66365). Sequences corresponding to the putative ®rst exon of CDK6 were then compared to the nucleotide sequence of CDK4 via the CLUSTAL sequence alignment program to identify intron/exon boundaries. Exon 1 and the¯anking intronic sequences of CDK6 were identi®ed within human BAC clone GS119P05 from chromosome 7q21 (Genbank Accession Number AC004011; Figure 2 ). When the sequences of CDK4 and CDK6 were compared, we found that the two kinases were highly homologous in their exon structure, with very similar sequence at the intron/exon boundaries. As shown schematically in Figure 1 , the region encoding the putative CDKN2A-binding site in CDK6 was found to lie within exon 1 (whereas in CDK4 this region is found in exon 2). This dierence re¯ects the fact that the ®rst exon of CDK4 is entirely untranslated, whereas in CDK6, the published untranslated sequence upstream of the initiation codon is found directly 5' to the ATG. In order to screen the R31 (R24) region, we again employed direct sequencing of PCR products. Oligonucleotides for PCR (Table 2) were designed in the 5' untranslated region and intron 1 so as to ensure the Figure 1 Genomic structural homology of CDK4 and CDK6. CDK4 structure is taken from Zuo et al. (1996) and deduced CDK6 structure is shown for comparison. Note that CDK6 intronic sizes are not known. The enlargement at the bottom shows amino acid homology between CDK4 and CDK6 within the region of CDK4 involved in binding to CDKN2A, with the position of R24/R31 indicated Table 1 Breakdown of 60 kindreds analysed in this study, using similar criteria to Sou®r et al. (1998) .
At least one individual At least two affected At least one individual At least one individual Number of families with Number of families with with multiple primary individuals are first diagnosed with melanoma with pancreatic two melanomas or three or more melanomas melanomas degree relatives prior to age 30 years carcinoma pancreatic carcinomas or pancreatic carcinomas
Totals 33 27 *Patient sampled would be an obligate carrier of any familial mutation found. All patients lacked coding or splice site mutations in exons 1 and 2 of the CDKN2A gene as well as within 1 kilobase (KB) upstream of the ATG initiation codon that comprises the promoter and 5' untranslated region (5'UTR). Most of the patients (53/60) had visited the Familial Melanoma Clinic at the Toronto-Sunnybrook Regional Cancer Centre (Toronto, Ontario, Canada) between March 1996 and March 1999, where they were questioned in detail regarding their family history of malignant melanoma, and had provided written informed consent to participate in the study. These patients ranged in age from 22 ± 70 years at the onset of the study, with the age at the ®rst diagnosis of melanoma ranging from 19 ± 63 years. In addition, seven families residing in various regions of the United States were included. The families had been followed prospectively for 4 ± 22 years and had consented to participate under an NIH IRB-approved protocol ampli®cation of the entire ®rst exon, including the region corresponding to codon 24 of CDK4 (codon 31 of CDK6), the putative CDKN2A binding site. By this method, we were able to sequence the entire length of exon 1 of CDK6 (encompassing amino acids 1 ± 77) and found no evidence of mutations in this region. Due to the lack of germline mutations described in the literature in exons 3 ± 8 of CDK4, we elected not to proceed with SSCP analysis of the remaining exons of CDK6. Considering the frequency and functional consequences of the inactivating CDKN2A mutations found in melanoma-prone individuals, the very low frequency of germline mutations found in the two downstream targets of this cyclin-dependant kinase inhibitor is perhaps surprising. As the majority of these mutations have the net eect of increasing CDK4 and CDK6 protein activity (via reduced p16 binding), it would follow that mutations in the p16-interactive coding regions could lead to similar cell cycle deregulation as do mutations in CDKN2A. We found this not to be the case. Several other mechanisms (e.g. enhancer mutations, alternative RNA splicing) may ultimately prove to oer a means of inactivation of CDKN2A and provide the hereditary basis of melanoma in kindreds linked to 9p21, but without CDKN2A mutations. However, in the absence of accurate linkage data to 9p21 in all kindreds, the possibility still exists that another as yet unidenti®ed melanoma susceptibility locus is responsible for the melanoma susceptibility in these families. Leukocyte DNA was extracted from peripheral blood samples using standard methods (Miller et al., 1988) . Exon 1 of CDK6 was analysed by direct cycle sequencing. The reaction mixture for the CDK6 PCR contained 2.5 units of Thermus aquaticus (Taq) DNA polymerase, 1 6 Taq DNA polymerase reaction buer, 2 mM MgC1 2 (Gibco/BRL), 0.2 mM dNTPs (Amersham Pharmacia Biotech, Piscataway, NJ, USA), 0.5 mM of each of the forward and reverse primers and 50 ng of patient DNA. The samples were denatured at 988C for 5 min and then subjected to 30 cycles of: denaturation at 988C for 30 s; annealing at 628C for 30 s; extension at 728C for 1 min and a 5 min 728C ®nal extension in a GeneAmp 2400 thermal cycler (Perkin-Elmer, Foster City, CA, USA). The quality and quantity of all PCR products was evaluated on a 1% agarose gel containing 1 mg/ml ethidium bromide. PCR reaction products were puri®ed using the QIAquick PCR puri®cation kit (Qiagen, Chatsworth, CA, USA) prior to sequencing, and 30 ± 50 ng of DNA were subsequently subjected to cycle sequencing using a¯uorescence-tagged primer (CDK6F*) and the Thermo Sequenase Cycle Sequencing Core Kit (Visible Genetics Inc., Toronto, Ontario). The samples were denatured at 948C for 2 min, then subjected to 35 cycles consisting of: denaturation at 948C for 30 s, annealing at 628C for 30 s; and extension at 728C for 1 min. After a ®nal 2 min extension at 728C, 4 ml of loading dye (Visible Genetics) was added to each reaction tube. The samples were heated at 958C for 2 min and placed on ice. Aliquots were then loaded onto a MicroGene Blaster TM automated sequencing system (Visible Genetics) for analysis. We assayed for germline mutations in CDK4 using either sequencing (exon 2), or SSCP (exons 3 ± 8) (exon 1 of CDK4 was not sequenced as it is non-coding). For CDK4 analysis, a similar PCR cycling protocol to that used for CDK6 was employed, but with an annealing temperature of 638C. Sequencing reactions were also performed as outlined above, using the¯uorescence-tagged primer CDK4F* and with an annealing temperature of 558C. Exons 3 ± 8 of CDK4 were analysed by SSCP using oligonucleotides and PCR protocols described by Zuo et al. (1996) . After puri®cation using the QIAquick PCR puri®cation kit (Qiagen, Chatsworth, CA, USA), the DNA fragments were subjected to endlabelling with 1.5 units of T4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA), and 5 mCi of [g-] 32 P ATP (ICN Biomedicals, Costa Mesa, CA, USA) for 45 min at 378C. Aliquots (3 ± 5 ml) of the labelled PCR fragments were denatured for 3 ± 5 min at 958C in an equal volume of stop solution (0.3% Bromphenol Blue, 0.3% Xylene Cyanol FF, 10 mM EDTA (pH 7.5), 97.5% deionized formamide). For analysis, 3 ± 5 ml of the denatured samples were loaded onto a non-denaturing gel containing 10% glycerol (16TBE, 6% acrylamide) and electrophoresed at 6 W at room temperature for approximately 16 h. The gels were then dried and exposed to X-ray ®lm at 7708C for 2 ± 24 h
